Diglyceride-containing blood fat reducing composition as well as preparation method and application thereof

Abstract

The invention provides a diglyceride-containing blood fat reducing composition as well as a preparation method and application thereof, and belongs to the technical field of biological medicines and foods. The composition for reducing blood fat is prepared from 70 to 80 parts of diglyceride oil, 10 to 20 parts of astaxanthin and 5 to 10 parts of chestnut mushroom polysaccharide. The blood fat reducing composition can effectively reduce the level of total cholesterol and triglyceride and adjust the level of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, and the blood fat reducing effect is remarkable. The diglyceride oil, the astaxanthin and the chestnut mushroom polysaccharide have no incompatibility, are relatively high in safety, and can be used for preparing lipid-lowering drugs or functional foods for assisting in lowering blood lipid so as to prevent or treat dyslipidemia.

Description

Technical Field

[0001] The present invention relates to the fields of biomedicine and food technology, and in particular to a diglyceride-containing lipid-lowering composition, a preparation method and application thereof. Background Art

[0002] Blood lipids, a general term for total cholesterol (TC), triglycerides (TG), and lipids (phospholipids, glycolipids, lipoproteins, sterols, and steroids) in plasma, are widely present in the human body and are essential for life activities and cellular metabolism. The most clinically relevant blood lipids are TC, TG, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). In recent years, with the gradual improvement in living standards, the prevalence of dyslipidemia has increased significantly. Dyslipidemia is closely related to diet and lifestyle, and dietary therapy and lifestyle changes are fundamental measures for its treatment. Among these, a low-fat, low-calorie, high-unsaturated fatty acid, high-fiber diet has become a consensus in the prevention and treatment of dyslipidemia. Due to the influence of living conditions, work pressure, traditional eating habits and other factors, it is difficult for most people to strictly control their dietary structure. As dyslipidemia occurs and symptoms worsen, many patients have to receive drug treatment. However, blood lipid regulating drugs such as statins, fibrates, niacin, cholesterol absorption inhibitors, probucol, bile acid sequestrants, etc. all have certain liver, muscle and kidney toxicity, and the incidence of adverse reactions is high after long-term use.

[0003] Diglyceride is a component in natural oils and fats. Its content in ordinary edible oils is not high, but its proportion can be increased industrially through enzyme treatment. Diglyceride can be used as a functional food for the treatment of obesity. In particular, 1,3-diglyceride can inhibit the accumulation of body fat, reduce serum triglyceride levels, and is effective for postprandial hyperlipidemia. It can reduce the content of postprandial hemoglobin A1c and increase postprandial lipid oxidation. Long-term consumption can achieve the purpose of weight loss and can be used for conditions such as excessive obesity, impaired glucose metabolism, and dyslipidemia. However, its lipid-lowering effect (especially the effect of reducing low-density lipoprotein cholesterol (LDL-C)) is usually not as significant as standard drug treatments such as statins, and individual differences are large. For patients with severe hyperlipidemia, DAG oil alone may not be enough to achieve the treatment goal. Therefore, it is necessary to provide a lipid-lowering composition to improve its lipid-lowering effect. Summary of the Invention

[0004] In view of this, the present invention provides a lipid-lowering composition containing diglyceride, a preparation method and application thereof, to solve the problem that diglyceride oil alone has a poor lipid-lowering effect.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The invention provides a diglyceride-containing blood lipid-lowering composition, which comprises the following components in parts by mass: 70-80 parts of diglyceride oil, 10-20 parts of astaxanthin, and 5-10 parts of chestnut mushroom polysaccharide.

[0007] Preferably, the diglyceride oil comprises 1,3-diglyceride.

[0008] Preferably, the diglyceride content in the diglyceride oil is ≥40%.

[0009] The present invention also provides a method for preparing the lipid-lowering composition, comprising the following steps:

[0010] (1) Mixing chestnut mushrooms with water, soaking and extracting at 60-70° C. for 30-60 minutes to obtain a chestnut mushroom extract;

[0011] (2) performing rotary evaporation on the chestnut mushroom extract to concentrate the chestnut mushroom extract to 20-30% of the original volume to obtain a chestnut mushroom extract concentrate;

[0012] (3) mixing the chestnut mushroom extract concentrate with anhydrous ethanol, allowing it to stand and centrifuge, and collecting the precipitate to obtain the chestnut mushroom crude polysaccharide;

[0013] (4) dissolving the crude chestnut mushroom polysaccharide in water to obtain a crude polysaccharide solution, and removing protein from the crude polysaccharide solution by sevage method to obtain a chestnut mushroom polysaccharide solution;

[0014] (5) After the chestnut mushroom polysaccharide solution is precipitated with alcohol, the precipitate is collected and freeze-dried to obtain chestnut mushroom polysaccharide;

[0015] (6) Mix diglyceride oil, astaxanthin and chestnut mushroom polysaccharide to obtain.

[0016] Preferably, the mass volume ratio of the chestnut mushroom to water is 1g:20-26mL.

[0017] Preferably, the volume ratio of the chestnut mushroom extract concentrate to anhydrous ethanol is 1:3.5-4.5.

[0018] Preferably, the centrifugal speed is 4500-5500 rpm, and the centrifugal time is 20-30 min.

[0019] Preferably, the concentration of the crude polysaccharide solution is 0.8-1.2 mg / mL.

[0020] The present invention also provides the use of the lipid-lowering composition in the preparation of lipid-lowering drugs.

[0021] The present invention also provides the use of the lipid-lowering composition in preparing functional foods that assist in lowering lipids.

[0022] By adopting the above technical solution, the present invention has the following beneficial effects:

[0023] (1) The lipid-lowering composition of the present invention can effectively reduce total cholesterol and triglyceride levels, regulate high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels, and has a significant lipid-lowering effect. The combined use of diglyceride oil, astaxanthin, and chestnut mushroom polysaccharide can overcome the problem that diglyceride oil alone is not effective in lowering low-density lipoprotein cholesterol.

[0024] (2) The diglyceride oil, astaxanthin and chestnut mushroom polysaccharide in the lipid-lowering composition of the present invention have no incompatibility and are highly safe. They can be used as a dietary control method for a long time without side effects to prevent or treat dyslipidemia. DETAILED DESCRIPTION

[0025] The invention provides a diglyceride-containing blood lipid-lowering composition, which comprises the following components in parts by mass: 70-80 parts of diglyceride oil, 10-20 parts of astaxanthin, and 5-10 parts of chestnut mushroom polysaccharide.

[0026] In the diglyceride-containing lipid-lowering composition of the present invention, the mass fraction of the diglyceride oil is 70 to 80 parts, preferably 72 to 78 parts, and more preferably 75 parts;

[0027] The mass fraction of the astaxanthin is 10 to 20 parts, preferably 13 to 17 parts, and more preferably 15 parts;

[0028] The mass fraction of the chestnut mushroom polysaccharide is 5 to 10 parts, preferably 7 to 9 parts, and more preferably 8 parts.

[0029] In the diglyceride-containing lipid-lowering composition of the present invention, the diglyceride oil includes 1,3-diglyceride; and the content of diglyceride in the diglyceride oil is ≥40%.

[0030] The present invention also provides a method for preparing the lipid-lowering composition, comprising the following steps:

[0031] (1) mixing chestnut mushrooms with water, soaking and extracting at 60-70° C. for 30-60 minutes to obtain a chestnut mushroom extract;

[0032] (2) performing rotary evaporation on the chestnut mushroom extract to concentrate the chestnut mushroom extract to 20-30% of the original volume to obtain a chestnut mushroom extract concentrate;

[0033] (3) mixing the chestnut mushroom extract concentrate with anhydrous ethanol, allowing it to stand and centrifuge, and collecting the precipitate to obtain the chestnut mushroom crude polysaccharide;

[0034] (4) dissolving the crude chestnut mushroom polysaccharide in water to obtain a crude polysaccharide solution, and removing protein from the crude polysaccharide solution by sevage method to obtain a chestnut mushroom polysaccharide solution;

[0035] (5) After the chestnut mushroom polysaccharide solution is precipitated with alcohol, the precipitate is collected and freeze-dried to obtain chestnut mushroom polysaccharide;

[0036] (6) Mix diglyceride oil, astaxanthin and chestnut mushroom polysaccharide to obtain.

[0037] The present invention firstly mixes chestnut mushrooms with water for extraction to obtain a chestnut mushroom extract; the mass volume ratio of chestnut mushrooms to water is 1g:20-26mL, preferably 1g:22-24mL, more preferably 1g:23mL; the extraction temperature is 60-70°C, preferably 62-68°C, more preferably 65°C; the extraction time is 30-60min, preferably 40-50min, more preferably 45min;

[0038] The present invention performs rotary evaporation on a chestnut mushroom extract to obtain a chestnut mushroom extract concentrate; the rotary evaporation temperature is 70-80° C., preferably 73-78° C., more preferably 75° C.; the rotary evaporation speed is 180-220 rpm, preferably 190-210 rpm, more preferably 200 rpm; and the chestnut mushroom extract is concentrated to 20-30% of the original volume, preferably 22-28%, more preferably 25%;

[0039] The method comprises mixing a chestnut mushroom extract concentrate with anhydrous ethanol, allowing the mixture to stand and centrifuge, and collecting a precipitate to obtain chestnut mushroom crude polysaccharide; the volume ratio of the chestnut mushroom extract concentrate to the anhydrous ethanol is 1:3.5-4.5, preferably 1:3.7-4.2, and more preferably 1:4; the standing time is 10-14 hours, preferably 11-13 hours, and more preferably 12 hours; the centrifugal speed is 4500-5500 rpm, preferably 4800-5200 rpm, and more preferably 5000 rpm; and the centrifugal time is 20-30 minutes, preferably 22-28 minutes, and more preferably 25 minutes.

[0040] The present invention dissolves the crude chestnut mushroom polysaccharide in water to obtain a crude polysaccharide solution, and removes protein from the crude polysaccharide solution by a sevage method to obtain the chestnut mushroom polysaccharide solution; the concentration of the crude polysaccharide solution is 0.8 to 1.2 mg / mL, preferably 0.9 to 1.1 mg / mL, and more preferably 1 mg / mL;

[0041] After the chestnut mushroom polysaccharide solution is precipitated with alcohol, the precipitate is collected and freeze-dried to obtain chestnut mushroom polysaccharide. The diglyceride, astaxanthin and chestnut mushroom polysaccharide are mixed to obtain the lipid-lowering composition.

[0042] The present invention also provides the use of the lipid-lowering composition in the preparation of lipid-lowering drugs.

[0043] The present invention also provides the use of the lipid-lowering composition in preparing functional foods that assist in lowering lipids.

[0044] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0045] The diglyceride oil in the embodiment of the present invention is "Xiqiao Mountain soybean oil", which was purchased from Guangzhou Yonghua Special Medical Nutrition Technology Co., Ltd., with a diglyceride content of 50%. Food-grade astaxanthin was purchased from Hebei Kelongduo Biotechnology Co., Ltd.

[0046] Example 1

[0047] (1) Mix chestnut mushrooms with water at a mass volume ratio of 1 g:20 mL, soak and extract at 60°C for 60 min to obtain a chestnut mushroom extract;

[0048] (2) subjecting the chestnut mushroom extract to rotary evaporation at 70° C. and 180 rpm to concentrate the chestnut mushroom extract to 20% of the original volume, thereby obtaining a chestnut mushroom extract concentrate;

[0049] (3) The chestnut mushroom extract concentrate was mixed with anhydrous ethanol at a volume ratio of 1:4.5, allowed to stand for 10 h, and centrifuged at 4500 rpm for 30 min. The precipitate was collected and washed three times with distilled water to obtain the crude chestnut mushroom polysaccharide;

[0050] (4) dissolving the crude polysaccharide of chestnut mushroom in distilled water to obtain a crude polysaccharide solution with a concentration of 0.8 mg / mL; and performing the sevage method three times to remove the protein in the polysaccharide solution to obtain a chestnut mushroom polysaccharide solution;

[0051] (5) After the chestnut mushroom polysaccharide solution was precipitated with alcohol, the precipitate was collected, washed with distilled water three times, and then freeze-dried to obtain chestnut mushroom polysaccharide;

[0052] (6) 70 g of diglyceride oil, 10 g of astaxanthin and 5 g of chestnut mushroom polysaccharide were mixed to obtain a lipid-lowering composition.

[0053] Example 2

[0054] (1) Mix chestnut mushrooms with water at a mass volume ratio of 1 g:24 mL, soak and extract at 65°C for 45 min to obtain a chestnut mushroom extract;

[0055] (2) performing rotary evaporation on the chestnut mushroom extract at 75° C. and 200 rpm to concentrate the chestnut mushroom extract to 25% of the original volume to obtain a chestnut mushroom extract concentrate;

[0056] (3) The chestnut mushroom extract concentrate was mixed with anhydrous ethanol in a volume ratio of 1:4, allowed to stand for 12 h, and centrifuged at 5000 rpm for 25 min. The precipitate was collected and washed three times with distilled water to obtain the crude chestnut mushroom polysaccharide;

[0057] (4) dissolving the crude polysaccharide of chestnut mushroom in distilled water to obtain a crude polysaccharide solution with a concentration of 1 mg / mL; and performing the sevage method three times to remove the protein in the polysaccharide solution to obtain a chestnut mushroom polysaccharide solution;

[0058] (5) After the chestnut mushroom polysaccharide solution was precipitated with alcohol, the precipitate was collected, washed with distilled water three times, and then freeze-dried to obtain chestnut mushroom polysaccharide;

[0059] (6) 75 g of diglyceride oil, 15 g of astaxanthin and 8 g of chestnut mushroom polysaccharide were mixed to obtain a lipid-lowering composition.

[0060] Example 3

[0061] (1) Mix chestnut mushrooms with water at a mass volume ratio of 1 g:26 mL, soak and extract at 70°C for 30 min to obtain a chestnut mushroom extract;

[0062] (2) subjecting the chestnut mushroom extract to rotary evaporation at 80° C. and 220 rpm to concentrate the chestnut mushroom extract to 30% of the original volume, thereby obtaining a chestnut mushroom extract concentrate;

[0063] (3) The chestnut mushroom extract concentrate was mixed with anhydrous ethanol at a volume ratio of 1:3.5, allowed to stand for 10 to 14 hours, and centrifuged at 5500 rpm for 20 minutes. The precipitate was collected and washed three times with distilled water to obtain the chestnut mushroom crude polysaccharide;

[0064] (4) dissolving the crude polysaccharide of chestnut mushroom in distilled water to obtain a crude polysaccharide solution with a concentration of 1.2 mg / mL; and performing the sevage method three times to remove the protein in the polysaccharide solution to obtain a chestnut mushroom polysaccharide solution;

[0065] (5) After the chestnut mushroom polysaccharide solution was precipitated with alcohol, the precipitate was collected, washed with distilled water three times, and then freeze-dried to obtain chestnut mushroom polysaccharide;

[0066] (6) 80 g of diglyceride oil, 20 g of astaxanthin and 10 g of chestnut mushroom polysaccharide were mixed to obtain a lipid-lowering composition.

[0067] Comparative Example 1

[0068] Different from Example 1, the lipid-lowering component only contains diglyceride oil.

[0069] Comparative Example 2

[0070] Different from Example 1, the lipid-lowering component only contains astaxanthin.

[0071] Comparative Example 3

[0072] The difference from Example 1 is that the blood lipid-lowering component only contains chestnut mushroom polysaccharide.

[0073] Experimental example

[0074] 1. Experimental Animals

[0075] Ninety healthy SPF-grade SD rats (male) weighing 180-200 g were purchased from Wuhan Plait Biopharmaceutical Technology Co., Ltd.

[0076] 2. Establishment of Hyperlipidemia Rat Model

[0077] After one week of adaptive feeding, SD rats were randomly divided into two groups: a blank control group (10 rats) and a hyperlipidemia model group (80 rats). The blank group animals were fed with ordinary feed from the beginning to the end of the experiment, while the hyperlipidemia model group animals were fed with a high-fat, high-cholesterol feed. After 12 weeks, blood was collected from the tail tip. The total cholesterol (TC) and triglyceride (TG) levels in the serum of the hyperlipidemia model group animals were significantly higher than those in the blank control group, indicating that the model was successfully established.

[0078] 3. Animal Grouping and Experiment

[0079] The hyperlipidemia model rats were randomly divided into 8 groups (10 rats per group): model group, positive control group, experimental group 1, experimental group 2, experimental group 3, and comparative group 1, comparative group 2, and comparative group 3. During the dosing period, the positive control group received lovastatin at 4 mg / kg / day; experimental group 1 received the composition of Example 1 at 400 mg / kg / day; experimental group 2 received the composition of Example 2 at 400 mg / kg / day; and experimental group 3 received the composition of Example 3 at 400 mg / kg / day. Comparative groups 1-3 received the diglyceride oil, astaxanthin, and chestnut mushroom polysaccharide from Comparative Examples 1-3, respectively, at 400 mg / kg / day. The blank group and model group received the same volume of purified water. During the dosing period, the blank group received a standard diet, while the other groups received a high-fat, high-cholesterol diet. Dosing continued for 30 days. After the last dose, the rats were fasted for 12 hours. Anesthesia was performed with an intraperitoneal injection of 3% sodium pentobarbital (1.2 mL / kg), and blood was collected from the abdominal aorta. The cells were centrifuged at 3000 rpm for 10 min, and the upper serum layer was collected. The contents of TC, TG, HDL, and LDL were detected using an automatic biochemical analyzer. The results are shown in Table 1.

[0080] Table 1 Blood lipid indexes of rats in each group

[0081]

[0082] As shown in Table 1, the effects of Examples 1 to 3 in lowering total cholesterol and low-density lipoprotein cholesterol are close to those of lovastatin used in the positive control group. Compared with the hyperlipidemia model group, the lipid-lowering effects of the compositions in Comparative Examples 1 to 3 are higher than the sum of the effects of Comparative Examples 1, 2, and 3, indicating that diglyceride oil, astaxanthin, and chestnut mushroom polysaccharide can synergistically exert a lipid-lowering effect, and the combined use of the three can overcome the problem of poor effect of diglyceride oil in lowering low-density lipoprotein cholesterol when used alone. Compared with the blank control group, the lipid-lowering compositions in Examples 1 to 3 significantly reduced hyperlipidemia symptoms after continuous gavage for 30 days, approaching the blood lipid level of the blank control group, and the mortality rate during the experiment was 0, indicating that the lipid-lowering composition of the present invention is safe and non-toxic and can be used to prepare lipid-lowering drugs or functional foods that assist in lowering lipids.

[0083] As can be seen from the above examples, the present invention provides a lipid-lowering composition containing diglyceride, and its preparation method and application. The lipid-lowering composition containing diglyceride of the present invention can effectively lower total cholesterol and triglyceride levels, regulate high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels, and has a significant lipid-lowering effect.

[0084] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A diglyceride-containing lipid-lowering composition, characterized in that: The invention comprises the following components in parts by mass: 70-80 parts of diglyceride oil, 10-20 parts of astaxanthin and 5-10 parts of chestnut mushroom polysaccharide.

2. The composition according to claim 1, characterized in that The diglyceride oil includes 1,3-diglyceride.

3. The composition according to claim 1, characterized in that The diglyceride content in the diglyceride oil is ≥40%.

4. The method for preparing the lipid-lowering composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) Mixing chestnut mushrooms with water, soaking and extracting at 60-70° C. for 30-60 minutes to obtain a chestnut mushroom extract; (2) performing rotary evaporation on the chestnut mushroom extract to concentrate the chestnut mushroom extract to 20-30% of the original volume to obtain a chestnut mushroom extract concentrate; (3) mixing the chestnut mushroom extract concentrate with anhydrous ethanol, allowing it to stand and centrifuge, and collecting the precipitate to obtain the chestnut mushroom crude polysaccharide; (4) dissolving the crude chestnut mushroom polysaccharide in water to obtain a crude polysaccharide solution, and removing protein from the crude polysaccharide solution by sevage method to obtain a chestnut mushroom polysaccharide solution; (5) After the chestnut mushroom polysaccharide solution is precipitated with alcohol, the precipitate is collected and freeze-dried to obtain chestnut mushroom polysaccharide; (6) Mix diglyceride oil, astaxanthin and chestnut mushroom polysaccharide to obtain.

5. The preparation method according to claim 4, characterized in that The mass volume ratio of the chestnut mushroom to water is 1g:20-26mL.

6. The preparation method according to claim 4, characterized in that The volume ratio of chestnut mushroom extract concentrate to anhydrous ethanol is 1:3.5-4.

5.

7. The preparation method according to claim 4, characterized in that The centrifugal speed is 4500-5500 rpm, and the centrifugal time is 20-30 min.

8. The preparation method according to claim 4, characterized in that The concentration of the crude polysaccharide solution is 0.8-1.2 mg / mL.

9. Use of the lipid-lowering composition according to any one of claims 1 to 3 in the preparation of lipid-lowering drugs.

10. Use of the lipid-lowering composition according to any one of claims 1 to 3 in the preparation of functional foods that assist in lowering blood lipids.

Images